Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ICMT | O60725 | 1/20 | 0.64 |
| ▸ | CDC25A | P30304 | 1/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.60 |
| ▸ | CNR2 | P34972 | 8/20 | 0.51 |
| ▸ | DNM2 | P50570 | 4/20 | 0.51 |
| ▸ | CNR1 | P21554 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22411431 | 0.99 | ICMT (0.66) | ICMTCDC25AHTR2ACNR2DNM2 | |
| SCHEMBL27041029 | 0.95 | HTR2A (0.62) | ICMTCDC25AHTR2ACNR2DNM2 | |
| SCHEMBL10967590 | 0.89 | CDC25A (0.66) | ICMTCDC25ACNR2DNM2CNR1 | |
| SCHEMBL7749067 | 0.89 | HTR2A (0.66) | ICMTCDC25AHTR2ACNR2CNR1 | |
| SCHEMBL13131369 | 0.84 | CDC25A (0.72) | ICMTCDC25ACNR2DNM2CNR1 | |
| SCHEMBL8126918 | 0.84 | CDC25A (0.64) | ICMTCDC25ACNR2DNM2CNR1 | |
| SCHEMBL5462804 | 0.83 | CDC25A (0.70) | ICMTCDC25ACNR2DNM2CNR1 | |
| SCHEMBL4535061 | 0.83 | HTR2A (0.65) | HTR2A | |
| SCHEMBL17943470 | 0.83 | CDC25A (0.57) | ICMTCDC25AHTR2ACNR2DNM2 | |
| SCHEMBL8143904 | 0.81 | CDC25A (0.74) | ICMTCDC25ACNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230141310-A1 | HUMAN GUT MICROBIOME-DERIVED BIOSYNTHETIC ENZYMES FOR PRODUCTION OF FATTY ACID AMIDES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-05-11 | — | — | US | disclosed |
| US-20200299738-A1 | HUMAN GUT MICROBIOME-DERIVED BIOSYNTHETIC ENZYMES FOR PRODUCTION OF FATTY ACID AMIDES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2020-09-24 | — | — | US | disclosed |
| WO-2020185627-A1 | HUMAN GUT MICROBIOME-DERIVED BIOSYNTHETIC ENZYMES FOR PRODUCTION OF FATTY ACID AMIDES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2020-09-17 | — | — | WO | disclosed |
| CN-103304467-A | Method for preparing N-coffee acyl tryptamine by one-step process | SUZHOU UUGENE BIOPHARMA CO LTD | 2013-09-18 | — | — | CN | disclosed |
| CN-103304467-A | Method for preparing N-coffee acyl tryptamine by one-step process | SUZHOU UUGENE BIOPHARMA CO LTD | 2013-09-18 | — | — | CN | disclosed |
| US-7517895-B2 | Synthetic diazonamides | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2009-04-14 | — | — | US | disclosed |
| EP-1904443-A1 | NEW BENZOHETEROCYCLYLETHYLBENZAMIDE DERIVATIVES | BAYER CROPSCIENCE SA (FR) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007006734-A1 | NEW BENZOHETEROCYCLYLETHYLBENZAMIDE DERIVATIVES | BAYER CROPSCIENCE SA (FR) | 2007-01-18 | — | — | WO | disclosed |
| US-20060089397-A1 | Synthetic diazonamides | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2006-04-27 | — | — | US | disclosed |
| US-7022720-B2 | Synthetic diazonamides as novel anti-mitotic agents | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2006-04-04 | — | — | US | disclosed |
| US-20030100589-A1 | Synthetic diazonamides as novel anti-mitotic agents | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2003-05-29 | — | — | US | disclosed |
| CN-1365971-A | Antibacterial activity, induction, separation and synthesis of N-acyltryptamine derivative as plant protecting chemical | CHINESE AGRICULTRAL UNIV (CN) | 2002-08-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089397-A1 | Synthetic diazonamides | BUB1B, BUB1, CDK15 | ICMT 2816/4885CDC25A 6/4885HTR2A 3427/4885 |
| US-20030100589-A1 | Synthetic diazonamides as novel anti-mitotic agents | BUB1B, BUB1, BUB3 | ICMT 2869/4885CDC25A 10/4885HTR2A 3767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.